

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. §371**

SCH 1737

U.S. APPLICATION NO. (If known, see 37 CFR §1.5)

**09/508972**

INTERNATIONAL APPLICATION NO.

PCT/EP998/05741

INTERNATIONAL FILING DATE

10 September 1998

PRIORITY DATE CLAIMED

18 September 1997 et al.

TITLE OF INVENTION


PROCESS FOR THERAPEUTIC TREATMENT OF PROLIFERATIVE DISEASES

APPLICANT(S) FOR DO/EO/US

DINKELBORG, Ludger, et al.

**Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:**

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
  2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
  3. ☐ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
  4. ☒ A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.
  5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
    - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
    - b. ☒ has been transmitted by the International Bureau.
    - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
  6. ☒ A translation of the International Application into English (35 U.S.C. §371(c)(2)).
  7. ☐ A copy of the International Search Report (PCT/ISA/210).
  8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3))
    - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
    - b. ☐ have been transmitted by the International Bureau.
    - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
    - d. ☒ have not been made and will not be made.
  9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)).
  10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)).
  11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
  12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).
- Items 13. to 19. below concern document(s) or information included:**
13. ☐ An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98.
  14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§3.28 and 3.31 is included.
  15. ☒ A FIRST preliminary amendment.
    - ☐ A SECOND or SUBSEQUENT preliminary amendment.
  16. ☐ A substitute specification.
  17. ☐ A change of power of attorney and/or address letter.
  18. ☐ Certificate of Mailing by Express Mail
  19. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 CFR §1.5) <b>05/508972</b>		INTERNATIONAL APPLICATION NO. <b>PCT/EP98/05741</b>		ATTORNEY'S DOCKET NUMBER <b>SCH 1737</b>	
17. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR §1.492 (a) (1) - (5)):</b> Search Report has been prepared by the EPO or JPO..... \$840.00 International preliminary examination fee paid to USPTO (37 CFR §1.482)..... \$670.00 No international preliminary examination fee paid to USPTO (37 CFR §1.482) but international search fee paid to USPTO (37 CFR §1.445(a)(2))..... \$760.00 Neither international preliminary examination fee (37 CFR §1.482) nor international search fee (37 CFR §1.445(a)(2)) paid to USPTO..... \$970.00 International preliminary examination fee paid to USPTO (37 CFR §1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$96.00				<b>CALCULATIONS</b> PTO USE ONLY <hr/>	
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$840.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than months from the earliest claimed priority date (37 C.F.R. §1.492(e)). <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30				<b>\$130.00</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	29 - 20 =	9	x \$ 18.00	<b>\$162.00</b>	
Independent claims	7 - 3 =	4	x \$ 78.00	<b>\$312.00</b>	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 260.00	<b>\$0.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$1,444.00</b>	
Reduction of ½ for filing by small entity, if applicable. A Verified Small Entity Statement must also be filed (Note 37 C.F.R. §§1.9, 1.27, 1.28).					
<b>SUBTOTAL =</b>				<b>\$1,444.00</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than months from the earliest claimed priority date (37 C.F.R. §1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30					
<b>TOTAL NATIONAL FEE =</b>				<b>\$1,444.00</b>	
Fee for recording the enclosed assignment (37 C.F.R. §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§3.28, 3.31). \$40.00 per property.					
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1,444.00</b>	
				Amount to be refunded:	
				charged:	
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$1,444.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>13-3402</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>13-3402</u> . A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 C.F.R. §§1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. §1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO: <b>MILLEN, WHITE, ZELANO &amp; BRANIGAN, P.C.</b> Arlington Courthouse Plaza I 2200 Clarendon Boulevard, Suite 1400 Arlington, Virginia 22201 (703) 243-6333					
Filed: Monday, March 20, 2000 AJZ:æk				<div style="text-align: center;">   <hr/>         SIGNATURE  <hr/>         Anthony J. Zelano  <hr/>         NAME  <hr/>         27,969  <hr/>         REGISTRATION NUMBER       </div>	

**IN THE UNITED STATES DESIGNATED/ELECTED OFFICE**

International Application No. : PCT/EP98/05741  
International Filing Date : 10 September 1998  
Priority Date(s) Claimed : 18 September 1997, 18 September 1997  
and 23 September 1997  
Applicant(s) (DO/EO/US) : DINKELBORG, Ludger, et al.  
Title: PROCESS FOR THERAPEUTIC TREATMENT OF PROLIFERATIVE DISEASES

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to calculating the national fee, and prior to examination in the National Phase of the above-identified International application, please amend this application as follows, noting that if the claims of the above-identified International Application were amended under Articles 19 and/or 34 of the PCT, it is requested that examination in the U.S. National Phase be based on the claims as originally filed under the PCT and this Preliminary Amendment is based on the original claims.:

**IN THE CLAIMS:**

Claims 3, 4, 5 and 6, line 1: Delete "or 2".

Claim 7, line 1: Delete "5, or 6,".


Claims 8, 9, 10, 11, 12, 13, 14, 15, 16 and 17, line 1: Delete "or 2".

Claim 21, line 1: Change "claims 18 to 20" to -- claim 18 --.

**R e m a r k s**

The purpose of this Preliminary Amendment is to eliminate the multiple dependency of the claims in order to avoid the additional fee.

Respectfully submitted,

---

Anthony J. Zelano (27,969)  
Representative capacity  
MILLEN, WHITE, ZELANO & BRANIGAN, PC  
Arlington Courthouse Plaza I  
2200 Clarendon Boulevard, Suite 1400  
Arlington VA 22201  
Direct Dial: 703-812-5311  
Fax: 703-243-6410  
E-mail: zelano@mwzb.com

AJZ:aek

Filed: **Monday, March 20, 2000**

k:\pat\sch\1737\prelm amdt

WO 99/13920

PCT/EP98/05741

**Process for Therapeutic Treatment of Proliferative Diseases**

The invention pertains to the field of treatment of proliferative diseases and especially the treatment of vascular diseases such as, for example, arteriosclerosis.

It is known that ionizing radiation inhibits the proliferation of cells. A considerable number of neoplastic and non-neoplastic diseases have already been treated in this way (Fletcher, Textbook of Radiotherapy, Philadelphia, PA: Lea and Febiger, 1980, Hall, Radiobiology for the Radiologist, Philadelphia, PA: Lippincott, 1988).

An attempt has also already been made to treat arteriosclerotic diseases using this process. Arteriosclerosis is an inflammatory, fibroproliferative disease that is responsible for 50% of all deaths in the USA, Europe, and Japan (Ross 1993, Nature 362: 801-809). In its peripheral manifestation, it threatens the upkeep of the extremities; with its coronary manifestation, the risk of fatal myocardial infarction exists; and with supra-aortic infection, there is the threat of stroke.

At this time, arteriosclerosis is treated in various ways. In addition to conservative measures (e.g., lowering the cholesterol level in the blood) and the bypass operation, mechanical dilatation (angioplasty), as well as the intravascular removal of atheromatous tissue (atherectomy) of stenotic segments

in peripheral arteries and the coronaries have been established as alternatives in regular clinical practice.

As stated below, the above-mentioned methods are associated with a considerable number of drawbacks, however.

The value of mechanical recanalization processes is greatly diminished by vascular occlusions as a result of vascular tears and dissections, as well as acute thromboses (Sigwart et al. 1987, N. Engl. J. Med. 316: 701-706). Long-term success is jeopardized by the reoccurrence of constrictions (restenoses). The CAVEAT study thus revealed that of 1012 patients, the restenosis rate six months after intervention in coronary atherectomy was 50% and in coronary angioplasty even 57% (Topol et al. 1993, N. Engl. J. Med. 329: 221-227). In addition, abrupt vascular occlusion occurred in this study in 7% of the atherectomy patients and in 3% of the angioplasty patients. Nicolini and Pepine (1992, Endovascular Surgery 72: 919-940) report a restenosis rate of between 35 and 40% and an acute occlusion rate of 4% after angioplastic intervention.

To combat these complications, various techniques have been developed. These include the implantation of metal endoprostheses (stents), (Sigwart et al. 1987, N. Engl. J. Med. 316: 701-706; Strecker et al., 1990, Radiology 175: 97-102). The implantation of stents in large-caliber arteries, e.g., in occlusions in the axis in the pelvis, has already become a treatment modality that is to be applied primarily. The use of stents in femoral arteries has shown disappointing results, however, with a primary openness rate of 49% and a reocclusion

frequency of 43% (Sapoval et al., 1992, Radiology 184: 833-839). Similar unsatisfactory results have been achieved with currently available stents in coronary arteries (Kavas et al. 1992, J. Am. Coll. Cardiol. 20: 467-474).

Up until now, no pharmacological or mechanical interventions have been able to prevent restenosis (Muller et al. 1992, J. Am. Coll. Cardiol. 19: 418-432, Popma et al. 1991, Circulation 84: 14226-1436).

The reason for the restenoses frequently occurring after mechanical intervention is assumed to be that interventions induce a proliferation and migration of smooth muscle cells in the vascular wall. The latter result in a neointimal hyperplasia and the observed restenoses in the treated vessel sections (Cascells 1992, Circulation 86, 723-729, Hanke et al. 1990, Circ. Res. 67, 651-659, Ross 1993, Nature 362, 801-809).

An alternative process for treating arteriosclerotic diseases uses ionizing radiation. The use of ionizing radiation of external origin on restenosis is associated with the drawback, however, that upon administration the radiation dose is not limited just to the desired spot; rather, the surrounding (healthy) tissue is also undesirably exposed to the radiation. Thus, to date, various studies have come up with little to increase the chances of success (Gellmann et al. 1991, Circulation 84 Suppl. II: 46A-59A, Schwartz et al. 1992, J. Am. Coll. Cardiol. 19: 1106-1113).

These drawbacks, which occur when external radiation sources are used, can be overcome if gamma radiation is directly used

with restenosis via, e.g., a catheter in the vascular area. With this form of administration with iridium-192, a high radiation dose of 20 Gy is applied to the restenosis foci. Some works report on the almost complete prevention of restenosis after this intervention (Wiedermann et al. 1994, Am. J. Physiol. 267: H125-H132, Böttcher et al. 1994, Int. J. Radiation Oncology Biol. Phys. 29: 183-186, Wiedermann et al. 1994, J. Am. Coll. Cardiol. 23: 1491-1498, Liermann et al. 1994, Cardiovasc. Intervent. Radiol. 17: 12-16). A drawback to this method is, however, that the radiation dose of 20 Gy that is applied in this case is very high. Since the lesions are dispersed irregularly on the vascular wall, uniform administration of a defined dose is not possible using this technique. Moreover, treatment of large-caliber vessels is not possible since, because of the dose reduction from the iridium source, the dose that can be administered is not adequate.

Another possible way of inhibiting restenosis is the implantation of P-32-doped stents (Fischell et al. Stents III, Entwicklung, Indikationen und Zukunft, Konstanz [Development, Indications, and the Future, Constancy]: Kollath and Liermann, 1995). In this work, an activity of 0.2 kBq P-32 per centimeter of stent length was enough (corresponding to a radiation dose of 0.25 Gy) to achieve maximum inhibition of smooth vascular muscle cells in vitro. It was thus possible to show that not only  $\gamma$ -emitters but also  $\beta$ -emitters prevent the proliferation of smooth muscle cells. An advantage of this method is that the radiation dose administered is considerably lower than in all previously



mentioned interventions. At this low dose, the endothelial cells that line the vascular bed are not damaged (Fischell et al. Stents III, Entwicklung, Indikationen und Zukunft, Konstanz: Kollath and Liermann, 1995). This form of intervention is possible only once, however, namely when the stent is positioned. In addition, it is limited only to those interventions in which stents are used. The restenoses that occur in the far more common types of interventions, such as atherectomies and angioplasties, cannot be treated with this method. Because of the small range of action of the  $\beta$ -radiation, it is not possible to administer a uniform dose of energy to the entire lesion.

In addition to radiation therapy, a number of other therapeutic strategies are also used for inhibiting neointimal hyperplasias (restenoses). The latter comprise standard medicines for suppression of restenoses such as antithrombotic agents, platelet aggregation inhibitors, calcium antagonists, anti-inflammatory and antiproliferative substances, but also gene-therapy approaches. In this case, the inhibition of growth stimulators, e.g., by antisense oligonucleotides or the enhancement of inhibiting factors by expression-vector-plasmids and the virus-mediated gene integration, is possible. Also, Aptamer oligonucleotides can be used for inhibiting a wide variety of receptor-mediated processes, which play a decisive role in restenosis.

With great energy and care, substances have been studied over the years that were administered under strictly controlled conditions as a long-term treatment since the desired purpose was

theoretically to reduce the restenosis rate (Herrmann et al., 1993, Drugs 46: 18-52).

More than 50 controlled studies with different substance groups were performed, without yielding definite proof that the substances examined could seriously reduce the restenosis rate.

This also applies for topical administration, in which the substances are brought via a special balloon catheter to the site of action that is desired in each case. It has been shown, however, that the previously used substances are washed too quickly from the vascular wall to be able to be therapeutically effective. Moreover, additional vascular wall alterations, which even act to promote restenosis, are induced by these pressure-mediated liquid injections.

The object of this invention was therefore to develop a process for the treatment of proliferative diseases that overcomes the drawbacks of previously known treatment processes.

This object is achieved by this invention.

A process for therapeutic treatment of proliferative diseases was developed that is characterized in that first an administration catheter is placed at the site of the lesion, and a radioactive substance is topically administered via the catheter, then the catheter is removed, and the radioactive substance remains at the site of the lesion.

Since radioactive substances are transported via an administration catheter right to the wall of a blood vessel and remain there, the concentration of the radionuclide lasts long


enough to inhibit the proliferation of the cells and thus a restenosis.

The process according to the invention has some important advantages in comparison to known treatment processes. In comparison to a considerable number of studied compounds from a wide variety of classes, the topical administration of certain substances and with certain catheters results in a surprisingly high radioactive dose at the desired, pathologically altered spot. This procedure results in a highly effective radiation dose with a low systemic load. The radioactive substances have a long dwell time at the administration site, which results in a highly effective dose on the spot. They are dispersed in particular and uniformly in the pathological regions. The unbonded radioactive substances are quickly eliminated.

Since certain radioactive substances, which are described in more detail below, pass into the wall of the arteriosclerotically altered vessels, not only the cells of the intima that face the lumen, but also those of the media and adventitia are kept from proliferating. The proportion of the administered dose that passes through the cell membrane results in a high radiation dose, which is effective close to the cell core.



Owing to the sensitivity of proliferating cells to ionizing radiation, the process according to the invention is suitable not only for treatment of arteriosclerotic diseases, but also for the treatment of other proliferative diseases, such as, e.g., tumor diseases.

Suitable radioactive substances are those that have sufficiently high lipophilia to remain adhered to the plaque. For example, radiolabeled metal complexes are suitable, such as, e.g., metal complexes of bis-amine-oxime derivatives of general formula I



in which  $n = 0 - 3$ , and radicals  $R^1$  to  $R^8$  are the same or different and in each case stand for a hydrogen atom and/or for an unbranched, branched, cyclic or polycyclic  $C_1$ - $C_{100}$  alkyl,  $C_1$ - $C_{100}$  alkenyl,  $C_1$ - $C_{100}$  alkynyl,  $C_1$ - $C_{100}$  aryl,  $C_1$ - $C_{100}$  alkylaryl and/or  $C_1$ - $C_{100}$  arylalkyl radical, which optionally is substituted with fluorine, chlorine, bromine and/or iodine atoms, and/or hydroxy, oxo, carboxy, aminocarbonyl, alkoxycarbonyl, amino, aldehyde or alkoxy groups with up to 30 carbon atoms and/or optionally is interrupted and/or substituted by one or more heteroatoms from the series N, P, As, O, S, Se, and whereby radicals  $R^2$  and  $R^3$ ,  $R^4$  and  $R^5$  as well as  $R^6$  and  $R^7$  together optionally can stand for an oxygen atom. These compounds, together with a radionuclide, form a metal complex, which is then used for topical administration in the treatment of proliferative diseases.

Also suitable are the metal complexes of the  $N_2S_2$  derivatives of general formulas II and III



whereby  $R^9$  to  $R^{32}$  are the same or different and in each case stand for a hydrogen atom and/or for an unbranched, branched, cyclic or polycyclic  $C_1$ - $C_{100}$  alkyl,  $C_1$ - $C_{100}$  alkenyl,  $C_1$ - $C_{100}$  alkynyl,  $C_1$ - $C_{100}$  aryl,  $C_1$ - $C_{100}$  alkylaryl and/or  $C_1$ - $C_{100}$  arylalkyl radical, which optionally is substituted with fluorine, chlorine, bromine, and/or iodine atoms and/or hydroxy, oxo, carboxy, aminocarbonyl, alkoxy, carbonyl, amino, aldehyde, or alkoxy groups with up to 30 carbon atoms, and/or optionally is interrupted and/or substituted by one or more heteroatoms from the series N, P, As, O, S, Se,

and whereby radicals  $R^{11}$  and  $R^{12}$ ,  $R^{13}$  and  $R^{14}$ ,  $R^{15}$  and  $R^{16}$ , as well as  $R^{17}$  and  $R^{18}$  together optionally can stand for an oxygen atom, and n, m and p, independently of one another, mean 1 or 2.

Other suitable compounds, which are suitable for topical treatment after complexing with suitable radioisotopes, are tetrofosmin, sestamibi and furifosmin derivatives.  $^{99m}\text{Tc}$ -tetrofosmin can be obtained under the trade name Myoview<sup>TM</sup> from the Amersham Company;  $^{99m}\text{Tc}$ -sestamibi is marketed under the trade name Cardiolite<sup>(R)</sup> by the DuPont Company; and  $^{99m}\text{Tc}$ -furifosmin can be purchased under the trade name Technescan Q-12 from the Mallinckrodt Medical Company.

Together with a radionuclide, all these compounds form a metal complex that can then be used for topical administration in the treatment of proliferative diseases.

To form a metal complex, radionuclides can be introduced that are alpha-, beta- and/or gamma-radiators, positron-radiators, Auger electron-radiators, and fluorescence radiators, whereby  $\beta$ - as well as combined  $\beta/\gamma$ -radiators are preferred for therapeutic purposes.

Corresponding radionuclides are known to one skilled in the art. By way of example, the radionuclides of the elements of atomic numbers 27, 29-32, 37-39, 42-51, 62, 64, 70, 75, 77, 82, or 83 can be mentioned.

Preferred are the nuclides  $^{99m}\text{Tc}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{67}\text{Cu}$ ,  $^{90}\text{Y}$  and  $^{107}\text{Ag}$ ; especially preferred are nuclides  $^{186}\text{Re}$ ,  $^{188}\text{Re}$  and  $^{67}\text{Cu}$ .

The production of bis-amine-oxime derivatives is described in US Patents 5,506,345 and US 5,387,692; the production of  $N_2S_2$  derivatives is described in US Patent 5,279,811.

The production of tetrofosmin derivatives is described in European Patent Application EP 303 374; the production of furifosmin derivatives is described in US Patent 5,112,595. Sestamibi derivatives and their production are described in International Patent Application WO 89/02433.

Other suitable metal complexes have ligands that are derived from ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), or a macrocyclic compound, such as, e.g., tetraazacyclododecane. The production of these compounds is known to one skilled in the art and is, moreover, described in detail in the examples below.

Other suitable ligands are, e.g., porphyrin derivatives, as they are described in, e.g., DE 42 32 925 A1 and DE 43 05 523 A1. Metal complexes that are suitable for the process according to the invention can also be produced with radionuclides from these ligands.

Also suitable are radioactive thallium compounds of isotopes  $^{201}\text{Tl}$ ,  $^{207}\text{Tl}$ ,  $^{209}\text{Tl}$ , and  $^{210}\text{Tl}$ ; especially suitable is  $^{201}\text{TlCl}$ .

Radiolabeled colloidal solutions are also extremely well suited for the treatment of proliferative diseases and especially for topical administration.

Suitable colloidal solutions are the tin colloids that are described in the examples; especially suitable are the tin colloids that can be produced with the aid of a kit from the

Amersham Company ("Amerscan Zinnkolloid ( $^{99m}\text{Tc}$ ) - Markierungskit für die Leberszintigraphie [Amerscan Tin Colloid ( $^{99m}\text{Tc}$ ) - Labeling Kit for Liver Scintigraphy])." Other suitable colloids are, e.g., radioactive gold sol ( $^{198}\text{Au}$  colloid) and radiolabeled sulfur colloids as well as other physiologically compatible, radioactive colloidal solutions.

Suitable radionuclides for radioactive labeling of colloidal solutions are known to one skilled in the art. By way of example, the radionuclides of elements Ag, As, At, Au, Ba, Bi, Br, C, Co, Cr, Cu, F, Fe, Ga, Gd, Hg, Ho, I, In, Ir, Lu, Mn, N, O, P, Pb, Pd, Pm, Re, Rh, Ru, Sb, Sc, Se, Sm, Sn, Tb, Tc, or Y can be mentioned.

Preferred are the nuclides  $^{99m}\text{Tc}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{67}\text{Cu}$ ,  $^{90}\text{Y}$ ,  $^{153}\text{Sm}$ ,  $^{160}\text{Tb}$ ,  $^{162}\text{Tb}$ ,  $^{198}\text{Au}$ , and  $^{107}\text{Ag}$ .


The production of the colloidal solutions is generally done with a redox reaction or the alteration of pH in an aqueous or alcoholic solution in the presence of a radioactive salt. The colloid can be formed in the presence of a stabilizer or subsequently mixed with a surfactant or another stabilizing amphiphilic substance. Other production methods for suitable colloidal solutions are electrochemical methods, such as are described by, e.g., M. T. Reetz et al. in Angew. Chem. [Applied Chemistry] 1995, Vol. 107, p. 2461 ff. The production of the tin colloids is described in the examples below, as well as in the instructions of the labeling kit of the Amersham Company. The production of a gold colloid for diagnostic purposes is described in Patent DE 24 20 531 C3.



The size of the particles formed is in the range between 5 and 1000 nm, and in the case of the tin colloid it is between 300 and 600 nm.

As catheters that are suitable for topical administration of the substances according to the invention, the catheters that are sketched in Fig. 3 can be used. Especially suitable are multichamber balloon catheters (such as, e.g., Dispatch™, SciMed) and microperforated balloon catheters.

In the examples below, the process in the animal experiment is described. In addition, the production of some compounds that are suitable for use in this treatment process is described. In Examples 1 to 5, the process is implemented with <sup>99m</sup>Tc-labeled HMPAO, whereby the ligand HMPAO has the following structure:



(see also Radiopharmaceuticals, Chemistry and Pharmacology, edited by Adrian D. Nunn, 1992, page 53).

WO 99/13920

PCT/EP98/05741

**Example 1****Topical Administration of  $^{99m}\text{Tc}$ -HMPAO**

The test animal, a white New Zealand rabbit (internal animal identification no.: 1708, male, 3.7 kg of body weight), was prepared 4 weeks before the actual administration experiment as follows:

Under anesthesia (Rompun/Ketavet 1:2, 1 ml/kg of body weight, i.m. administration), the endothelium was damaged with a 2F Fogarthy balloon catheter in the arteria carotis dextra (balloon denudation). Then, the animal received a special diet with an addition of 0.2% cholesterol. The test animal developed an arteriosclerotic lesion on the balloon-denuded spot created by this pretreatment.

Topical administration of HMPAO that was labeled with technetium  $^{99m}$  is carried out on the anesthetized test animal (for type of anesthesia, see above) via a coronary perfusion/infusion catheter (dispatch 3.0, Xtra slippery coating, manufacturer: Boston Scientific Corporation, Ratingen) directly on the lesion in the carotid artery. The radioactive dose of 0.48 mCi (= 17.76 MBq) was administered in a volume of 0.85 ml.

During the entire experiment, the test animal was under a gamma camera (Elscint SP4 HR) to measure the dispersion of radioactivity in the body. The activity at the lesion is set as a proportion of the total activity (measured at this time in the animal). In the case of this test animal, there was found:

5 minutes post administration	55.38% of the dose at the lesion
4 hours post administration	46.78% of the dose at the lesion
24 hours post administration	21.45% of the dose at the lesion

## Example 2

### Topical Administration of $^{99m}\text{Tc}$ -HMPAO

The test animal, a white New Zealand rabbit (internal animal identification no.: 1856, male, 3.3 kg of body weight), was prepared 4 weeks before the actual administration experiment as follows:

Under anesthesia (Rompun/Ketavet 1:2, 1 ml/kg of body weight, i.m. administration), the endothelium was damaged with a 2F Fogarthy balloon catheter in the arteria carotis dextra (balloon denudation). Then, the animal received a special diet with an addition of 0.2% cholesterol. The test animal developed an arteriosclerotic lesion on the balloon-denuded spot created by this pretreatment.

The topical administration of the HMPAO that was labeled with technetium  $^{99m}\text{Tc}$  is carried out on the anesthetized test animal (for type of anesthesia, see above) via a coronary perfusion/infusion catheter (dispatch 3.0, Xtra slippery coating, manufacturer: Boston Scientific Corporation, Ratingen) directly on the lesion in the carotid artery. The radioactive dose of 1.91 mCi (= 70.67 MBq) was administered in a volume of 1.0 ml (flushing with 0.3 ml of physiological saline solution).

During the entire experiment, the test animal was under a gamma camera (Elscint SP4 HR) to measure the dispersion of

radioactivity in the body. The activity in the lesion is set as a proportion of the total activity (measured at this time in the animal). In the case of this test animal, there was found:

5 minutes post administration	40.74% of the dose at the lesion
4 hours post administration	35.13% of the dose at the lesion
24 hours post administration	23.69% of the dose at the lesion

### Example 3

#### Topical Administration of $^{99m}\text{Tc}$ -HMPAO

The test animal is a white New Zealand rabbit (internal animal identification no.: 1584, male, 3.4 kg of body weight).

Under anesthesia (Rompun/Ketavet 1:2, 1 ml/kg of body weight, i.m. administration), the endothelium was damaged with a balloon catheter in the infraranal aorta (balloon denudation). Then, over a period of 5 minutes, technetium  $^{99m}$ -labeled HMPAO was administered to the test animal via a microperforated balloon catheter (4 mm Match-35 PTA, Schneider Company, FRG). The radioactive dose of 0.64 mCi (= 23.68 MBq) was administered in a volume of 1 ml.

During the entire experiment, the test animal was under a gamma camera (Elscint SP4 HR) to measure the dispersion of radioactivity in the body. The activity in the lesion is set as a proportion of the total activity (measured at this time in the animal). In the case of this test animal, there was found:

5 minutes post administration	38.45% of the dose at the lesion
4 hours post administration	35.64% of the dose at the lesion
24 hours post administration	16.63% of the dose at the lesion

**Example 4****Topical Administration of  $^{99m}\text{Tc}$ -HMPAO**

The test animal was a white New Zealand rabbit (internal animal identification no.: 1587, male, 3.5 kg of body weight).

Under anesthesia (Rompun/Ketavet 1:2, 1 ml/kg of body weight, i.m. administration), the endothelium was damaged with a balloon catheter in the infraranal aorta (balloon denudation). Then, over a period of 5 minutes, technetium  $^{99m}\text{Tc}$ -labeled HMPAO was administered to the test animal via a microperforated balloon catheter (4 mm Match-35 PTA, Schneider Company, FRG). The radioactive dose of 1.18 mCi (= 43.66 MBq) was administered in a volume of 1 ml.

During the entire experiment, the test animal was under a gamma camera (Elscint SP4 HR) to measure the dispersion of radioactivity in the body. The activity in the lesion is set as a proportion of the total activity (measured at this time in the animal). In the case of this test animal, there was found:

5 minutes post administration	37.06% of the dose at the lesion
4 hours post administration	32.03% of the dose at the lesion
24 hours post administration	20.01% of the dose at the lesion

**Example 5****Topical Administration of  $^{99m}\text{Tc}$ -HMPAO**

The test animal was a white New Zealand rabbit (internal animal identification no.: 1586, male, 3.3 kg of body weight).

Under anesthesia (Rompun/Ketavet 1:2, 1 ml/kg of body weight, i.m. administration), the endothelium was damaged with a

balloon catheter in the infrarenal aorta (balloon denudation). Then, over a period of 5 minutes, technetium 99m-labeled HMPAO was administered to the test animal via a microperforated balloon catheter (4 mm Match-35 PTA, Schneider Company, FRG). The radioactive dose of 0.45 mCi (= 16.65 MBq) was administered in a volume of 1 ml.

During the entire experiment, the test animal is under a gamma camera (Elscint SP4 HR) to measure the dispersion of radioactivity in the body. The activity in the lesion is set as a proportion of the total activity (measured at this time in the animal). In the case of this test animal, there was found:

5 minutes post administration	45.56% of the dose at the lesion
4 hours post administration	36.39% of the dose at the lesion
24 hours post administration	15.24% of the dose at the lesion

#### **Example 6**

**Production of 1-{3-[N-(2-Methoxyethyl)-octadecylsulfamoyl]-2-hydroxy-propyl}-4,7,10-tetraaza-cyclododecane, Yttrium-90 Complex**

5 mg of 1-{3-[N-(2-methoxyethyl)-octadecylsulfamoyl]-2-hydroxypropyl}-4,7,10-tetraazacyclododecane (produced according to DE 4340809.5) is dissolved in 500  $\mu$ l of dimethyl sulfoxide and 50  $\mu$ l of 0.1M sodium acetate buffer (pH = 4.0). After 37 MBq of yttrium-90-trichloride solution is added, the reaction mixture is heated for 10 minutes to 100°C. The Y-90 complex solution that is thus prepared can be used without additional purification.

#### **Example 7**

**a) Production of N,N'-Bisundecyl-diethylene-triamine-pentaacetic acid Diamide**

3.57 g (10 mmol) of diethylene-triamine-pentaacetic acid bisanhydride is suspended together with 4.05 g (40 mmol) of triethylamine in 100 ml of absolute dimethylformamide. Then, a solution of 3.42 g (20 mmol) of undecylamine, dissolved in 50 ml of absolute dichloromethane, is added in drops to the reaction mixture at room temperature. The reaction batch is stirred for 6 hours at room temperature, filtered and concentrated by evaporation in a medium-high vacuum. The residue is dissolved three times in 100 ml of dimethylformamide and concentrated by evaporation in a medium-high vacuum in each case. 50 ml of absolute diethyl ether is poured over the foamy reaction product, and it is stirred overnight. It is filtered and dried in a medium-high vacuum.

Yield: 6.3 g (90%), white powder.

**Elementary analysis:**

Cld: C 61.77 H 9.94 N 10.01 O 18.86

Fnd: C 61.52 H 9.63 N 9.91 O

**b) Production of N,N'-bisundecyl-diethylenetriamine-pentaacetic acid diamide, yttrium-90 complex**

5 mg of N,N'-bisundecyl-diethylenetriamine-pentaacetic acid diamide (Example 7a) is dissolved in 500  $\mu$ l of dimethyl sulfoxide and 50  $\mu$ l of 0.1 M sodium acetate buffer (pH = 4.0). After 37 MBq of yttrium-90 trichloride solution is added, the reaction

mixture is allowed to stand for 10 minutes at room temperature. The Y-90 complex solution that is thus prepared can be used without additional purification.

### Example 8

#### a) Production of N-Benzylloxycarbonyl-glycyl-N'-undecyl-glycinamide

3.63 g (10 mmol) of N-benzylloxycarbonyl-glycyl-glycine-N-hydroxysuccinimide ester and 1.71 g (10 mmol) of undecylamine are dissolved in 100 ml of absolute dichloromethane. The reaction mixture is stirred for 6 hours at room temperature. Then, it is diluted with 100 ml of dichloromethane, the organic phase is washed twice with 50 ml of saturated sodium bicarbonate solution and once with 50 ml of water. It is dried on magnesium sulfate, and the solvent is evaporated in a vacuum. The crude product is purified by chromatography on silica gel (eluant: dichloromethane/methanol 95:5).

Yield: 3.8 g (90.6%), white powder.

Elementary analysis:

Clcd: C 65.84 H 8.89 N 10.01 O 15.25

Fnd: C 65.71 H 9.02 N 10.10 O

#### b) Production of Glycyl-N'-undecyl-glycinamide

3 g (7.15 mmol) of N-benzylloxycarbonyl-glycyl-N'-undecyl-glycinamide (Example 8a) is dissolved in 100 ml of absolute ethanol. After 300 mg of palladium is added to carbon (10%), it



is hydrogenated for 2 hours at room temperature (1 atmosphere of hydrogen). It is filtered and concentrated by evaporation in a vacuum. The resulting amine is used for subsequent reaction without additional purification.

Yield: 1.92 g (94.1%), white foam.

Elementary analysis:

Clcd: C 63.12 H 10.95 N 14.72 O 11.21

Fnd: C 63.03 H 11.04 N 14.57 O

**c) Production of N-(S-Acetyl-mercaptoacetyl)-glycyl-N'-undecyl-glycinamide**

285.4 mg (1 mmol) of glycyl-N'-undecyl-glycinamide (Example 8b) and 231.2 mg (1 mmol) of S-acetyl-mercapto-acetic acid-N-hydroxy-succinimide ester are dissolved together in 20 ml of absolute dichloromethane. The reaction mixture is stirred for 6 hours at room temperature. Then, it is diluted with 20 ml of dichloromethane, and the organic phase is washed twice with 5 ml of semi-saturated sodium bicarbonate solution and once with 5 ml of water. It is dried on magnesium sulfate, and the solvent is evaporated in a vacuum. The crude product is purified by chromatography on silica gel (eluant: dichloromethane/methanol 93:7).

Yield: 362 mg (90.1%), white powder

## Elementary analysis:

Cld: C 56.83 H 8.79 N 10.46 O 15.94 S 7.98

Fnd: C 56.67 H 8.93 N 10.18 O S 7.72

**d) Production of N-(Mercaptoacetyl)-glycyl-N'-undecyl-glycinamide**

201 mg (0.5 mmol) of N-(S-acetyl-mercaptoacetyl-glycyl-N'-undecyl-glycinamide (Example 8c) is dissolved in 15 ml of absolute ethanol. It is saturated with argon, and an ammonia stream is directed through the solution for 30 minutes. Then, it is concentrated by evaporation, and the residue is taken up in 20 ml of dichloromethane. The organic phase is shaken once with 2% aqueous citric acid and dried on sodium sulfate. The solvent is evaporated in a vacuum, and the residue is chromatographed on silica gel (eluant: dichloromethane/methanol 9:1).

Yield: 153 mg (85.1%), white powder

## Elementary analysis:

Cld: C 56.79 H 9.25 N 11.69 O 13.35 S 8.92

Fnd: C 56.67 H 9.43 N 11.48 O S 8.71

**e) Production of N-(Mercaptoacetyl)-glycyl-N'-undecyl-glycinamide, Re-186 Complex**

5 mg of N-(mercaptoacetyl)-glycyl-N'-undecyl-glycinamide (Example 8d) is dissolved in 800  $\mu$ l of ethanol. After 5 mg of disodium-L-tartrate and 50  $\mu$ l of 0.1 M sodium hydrogen phosphate buffer (pH = 8.5) are added, 37 MBq of perrhenate and 10  $\mu$ l of

tin dichloride-dihydrate solution (5 mg of  $\text{SnCl}_2 \times 2\text{H}_2\text{O}$ /1 ml of 0.1 M HCl) are added. The reaction mixture is heated for 5 minutes to 60°C. The thus prepared solution of the Re-186 complex of N-(mercaptoacetyl)-glycyl-N'-undecyl-glycinamide can be used without additional purification.

#### **Example 9**

##### **Production of N,N'-Bis[3,6,9,9-tetra(hydroxycarboxymethyl)-1-oxo-3,6,9-triaza-non-1-yl]-mesoporphyrin-IX-13,17-dihydrazide, Y-90 Complex**

5 mg of N,N'-bis[3,6,9-tri(hydroxycarboxymethyl)-9-(ethoxycarboxymethyl)-1-oxo-3,6,9-triaza-non-1-yl]-mesoporphyrin-IX-13,17-dihydrazide (produced according to DE 42 32 925 A1, Example 1a) is stirred in 5 ml of 0.1 M NaOH under argon atmosphere for 3 hours at room temperature. After saponification of the bis-ethyl ester (TLC monitoring) has been completed, it is set at pH = 6 with glacial acetic acid, and 37 MBq of yttrium-90-trichloride solution is added to the batch. It is stirred for 15 minutes at room temperature. HPLC analysis indicates 95% incorporation of the radioisotope.

#### **Example 10**

##### **Production of 5,10,15,20-Tetrakis-[3-(carboxymethoxy)-phenyl]-porphyrin, Yttrium-90 Complex**

2.0 mg of 5,10,15,20-tetrakis-[3-(carboxymethoxy)-phenyl]-porphyrin (produced according to DE 43 05 523 A1, Example 13a) is dissolved in 5 ml of acetic acid and mixed with a hydrochloric

acid solution of 1.0 mCi yttrium-90-chloride. The reaction mixture is autoclaved for one hour at 140°C, the solvent is evaporated in a vacuum, and the residue is taken up in 5 ml of water. By adding aqueous sodium bicarbonate solution in drops, it is set at pH 7.3, and the red solution that is produced is filtered with a membrane filter. HPLC monitoring of the filtrate can indicate an incorporation rate of > 95% of the activity used in the porphyrin ligands.

#### **Example 11**

##### **Production of 5,10,15,20-Tetrakis-[3-(carboxymethoxy)-phenyl]-porphyrin, Copper-67 Complex**

The production of the complex is described in DE 43 05 523 A1, Example 14.

#### **Example 12**

##### **Production of a Technetium-99m-tin Colloid**

555 MBq of sodium pertechnetate-99m in 2 ml of 0.9% sodium chloride solution is mixed at room temperature with 20 µl of tin(II) chloride solution (5 mg of tin(II) chloride-dihydrate/1 ml of 0.01 M HCl). After 10 minutes, it is diluted with 1 ml of PBS buffer. The solution that is obtained is slightly opalescent.

**Example 13****Production of a Rhenium-186-tin Colloid**

37 MBq of sodium perrhenate-186 in 2 ml of 0.9% sodium chloride solution is mixed at room temperature with 40  $\mu$ l of tin(II) chloride solution (5 mg of tin(II) chloride dihydrate/1 ml of 0.01 M HCl). After 10 minutes, it is diluted with 1 ml of PBS buffer. The solution that is obtained is slightly opalescent.

**Example 14****Topical Administration of a Tin Colloid**

The test animal is a white New Zealand rabbit (internal animal identification no.: 1852, male, 3.5 kg of body weight).

Under anesthesia (Rompun/Ketavet 1:2, 1 ml/kg of body weight, i.m. administration), the endothelium was damaged with a balloon catheter in the infraranal aorta (balloon denudation). Then, over a period of 5 minutes, tin colloid, which was produced according to the kit of the Amersham Company ("Amerscan Zinnkolloid ( $^{99m}\text{Tc}$ ) - Markierungskit für die Leberszintigraphie [Amerscan Tin Colloid ( $^{99m}\text{Tc}$ ) - Labeling Kit for Liver Scintigraphy]), was administered to the test animal with a microperforated Match catheter (balloon catheter with a 5 mm diameter; manufacturer: Schneider Company, Düsseldorf). The radioactive dose of 0.4 mCi (= 14.8 MBq) was administered in a volume of 0.1 ml.

During the entire experiment, the test animal is under a gamma camera (Elscint SP4 HR) to display the dispersion of

radioactivity in the body. In Fig. 1, the situation before administration is depicted in the upper part. The catheter that contains the tin colloid can be seen clearly. The arrow shows the balloon of the catheter, which is at the desired administration spot. In the lower part of the image, the same site is shown 1.5 hours after administration and removal of the catheter. The amount of tin colloid that remains at the administration spot is clearly visible.

### Example 15

#### Topical Administration of a Tin Colloid

The test animal is a white New Zealand rabbit (internal animal identification no.: 1839, male, 3.7 kg of body weight).

Under anesthesia (Rompun/Ketavet 1:2, 1 ml/kg of body weight, i.m. administration), the endothelium was damaged with a balloon catheter in the infraranal aorta (balloon denudation). Then, over a period of 5 minutes, tin colloid, which was produced according to the kit of the Amersham Company ("Amerscan Zinnkolloid ( $^{99m}\text{Tc}$ ) - Markierungskit für die Leberszintigraphie") was administered to the test animal with a microperforated Match catheter (balloon catheter with a 5 mm diameter; manufacturer: Schneider Company, Düsseldorf). The radioactive dose of 0.47 mCi (= 17.39 MBq) was administered in a volume of 0.1 ml.

During the entire experiment, the test animal was under a gamma camera (Elscint SP4 HR) to display the dispersion of radioactivity in the body. In Fig. 2, the situation before administration is depicted in the upper part. The catheter that

contains the tin colloid can be seen clearly. The arrow shows the balloon of the catheter, which is at the desired administration spot. In the lower part of the image, the same site is shown 1.5 hours after administration and removal of the catheter. The amount of tin colloid that remains at the administration spot is clearly visible.

WO 99/13920

PCT/EP98/05741


**Claims**

1. Process for therapeutic treatment of proliferative diseases, characterized in that first an administration catheter is placed on the site of the lesion, and a radioactive substance is administered topically via the catheter, then the catheter is removed, and the radioactive substance remains on the site of the lesion.

2. Process for therapeutic treatment of arteriosclerotic diseases, wherein first an administration catheter is placed on the site of the lesion, and a radioactive substance is administered topically via the catheter, then the catheter is removed, and the radioactive substance remains on the site of the lesion.

3. Process according to claim 1 or 2, wherein the radioactive substance is a metal complex.

4. Process according to claim 1 or 2, wherein the radioactive substance is a metal complex, whose ligand is a bis-amine-oxime derivative of general formula I,




(I)



in which  $n = 0 - 3$ , and radicals  $R^1$  to  $R^8$  are the same or different and in each case stand for a hydrogen atom and/or for an unbranched, branched, cyclic or polycyclic  $C_1-C_{100}$  alkyl,  $C_1-C_{100}$  alkenyl,  $C_1-C_{100}$  alkynyl,  $C_1-C_{100}$  aryl,  $C_1-C_{100}$  alkylaryl and/or  $C_1-C_{100}$  arylalkyl radical, which optionally is substituted with fluorine, chlorine, bromine and/or iodine atoms, and/or hydroxy, oxo, carboxy, aminocarbonyl, alkoxycarbonyl, amino, aldehyde or alkoxy groups with up to 30 carbon atoms and/or optionally is interrupted and/or substituted by one or more heteroatoms from the series N, P, As, O, S, Se, and whereby radicals  $R^2$  and  $R^3$ ,  $R^4$  and  $R^5$  as well as  $R^6$  and  $R^7$  together optionally can stand for an oxygen atom, and whose central atom is a radionuclide of the elements of atomic numbers 27, 29-32, 37-39, 42-51, 62, 64, 70, 75, 77, 82 or 83.


5. Process according to claim 1 or 2, wherein the radioactive substance is a metal complex, whose ligand is an  $N_2S_2$  derivative of general formula II,



whereby  $R^9$  to  $R^{20}$  are the same or different and in each case stand for a hydrogen atom and/or for an unbranched, branched, cyclic or polycyclic  $C_1-C_{100}$  alkyl,  $C_1-C_{100}$  alkenyl,  $C_1-C_{100}$  alkynyl,  $C_1-C_{100}$  aryl,  $C_1-C_{100}$  alkylaryl and/or  $C_1-C_{100}$  arylalkyl radical, which

optionally is substituted with fluorine, chlorine, bromine and/or iodine atoms and/or hydroxy, oxo, carboxy, aminocarbonyl, alkoxycarbonyl, amino, aldehyde or alkoxy groups with up to 30 carbon atoms, and/or optionally is interrupted and/or substituted by one or more heteroatoms from the series N, P, As, O, S, Se, and whereby radicals  $R^{11}$  and  $R^{12}$ ,  $R^{13}$  and  $R^{14}$ ,  $R^{15}$  and  $R^{16}$  as well as  $R^{17}$  and  $R^{18}$  together optionally can stand for an oxygen atom, and n, m and p, independently of one another, mean 1 or 2, and whose central atom is a radionuclide of the elements of atomic numbers 27, 29-32, 37-39, 42-51, 62, 64, 70, 75, 77, 82 or 83.

6. Process according to claim 1 or 2, wherein the radioactive substance is a metal complex, whose ligand is an  $N_2S_2$  derivative of general formula III,



whereby  $R^{21}$  to  $R^{32}$  are the same or different and in each case stand for a hydrogen atom and/or for an unbranched, branched, cyclic or polycyclic  $C_1$ - $C_{100}$  alkyl,  $C_1$ - $C_{100}$  alkenyl,  $C_1$ - $C_{100}$  alkynyl,  $C_1$ - $C_{100}$  aryl,  $C_1$ - $C_{100}$  alkylaryl and/or  $C_1$ - $C_{100}$  arylalkyl radical,

which optionally is substituted with fluorine, chlorine, bromine and/or iodine atoms and/or hydroxy, oxo, carboxy, aminocarbonyl, alkoxy carbonyl, amino, aldehyde or alkoxy groups with up to 30 carbon atoms, and/or optionally is interrupted and/or substituted by one or more heteroatoms from the series N, P, As, O, S, Se, and whose central atom is a radionuclide of the elements of atomic numbers 27, 29-32, 37-39, 42-51, 62, 64, 70, 75, 77, 82 or 83.

7. Process according to claim 4, 5, or 6, wherein a central atom, which is selected from the group  $^{99m}\text{Tc}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{67}\text{Cu}$ ,  $^{90}\text{Y}$  and  $^{107}\text{Ag}$ , contains the metal complex that is used.

8. Process according to claim 1 or 2, wherein the radioactive substance is a metal complex, whose ligand is a porphyrin derivative.

9. Process according to claim 1 or 2, wherein the radioactive substance is a thallium compound of isotopes  $^{201}\text{Tl}$ ,  $^{207}\text{Tl}$ ,  $^{209}\text{Tl}$  and  $^{210}\text{Tl}$ .

10. Process according to claim 1 or 2, wherein the radioactive substance is  $^{201}\text{TlCl}$ .

11. Process according to claim 1 or 2, wherein the radioactive substance is a tetrofosmin derivative.

12. Process according to claim 1 or 2, wherein the radioactive substance is a sestamibi derivative.

13. Process according to claim 1 or 2, wherein the radioactive substance is a furifosmin derivative.

14. Process according to claim 1 or 2, wherein


the radioactive substance is a colloidal solution with particle sizes of between 5 and 1000 nm.

15. Process according to claim 1 or 2, wherein the radioactive substance is  $^{99m}\text{Tc}$ -tin colloid or  $^{186}\text{Re}$ -tin colloid.

16. Process according to claim 1 or 2, wherein the catheter that is used is a microporous balloon catheter.

17. Process according to claim 1 or 2, wherein the catheter that is used is a multichamber balloon catheter.

18. Use of complexes whose ligand is a bis-amine-oxime derivative of general formula I




in which  $n = 0 - 3$ , and radicals  $R^1$  to  $R^8$  are the same or different and in each case stand for a hydrogen atom and/or for an unbranched, branched, cyclic or polycyclic  $C_1$ - $C_{100}$  alkyl,  $C_1$ - $C_{100}$  alkenyl,  $C_1$ - $C_{100}$  alkynyl,  $C_1$ - $C_{100}$  aryl,  $C_1$ - $C_{100}$  arylalkyl and/or  $C_1$ - $C_{100}$  arylalkyl radical, which optionally is substituted with fluorine, chlorine, bromine and/or iodine atoms and/or hydroxy, oxo, carboxy, aminocarbonyl, alkoxycarbonyl, amino, aldehyde or alkoxy groups with up to 30 carbon atoms and/or optionally is interrupted and/or substituted by one or more heteroatoms from the series N, P, As, O, S, Se, and whereby radicals  $R^2$  and  $R^3$ ,  $R^4$  and  $R^5$  as

well as  $R^6$  and  $R^7$  together optionally can stand for an oxygen atom,

and whose central atom is a radionuclide of the elements of atomic numbers 27, 29-32, 37-39, 42-51, 62, 64, 70, 75, 77, 82 or 83, for the production of agents that are administered topically in the treatment of proliferative diseases.


19. Use of complexes whose ligand is an  $N_2S_2$  derivative of general formula II



whereby  $R^9$  to  $R^{20}$  are the same or different and in each case stand for a hydrogen atom and/or for an unbranched, branched, cyclic or polycyclic  $C_1$ - $C_{100}$  alkyl,  $C_1$ - $C_{100}$  alkenyl,  $C_1$ - $C_{100}$  alkynyl,  $C_1$ - $C_{100}$  aryl,  $C_1$ - $C_{100}$  alkylaryl and/or  $C_1$ - $C_{100}$  arylalkyl radical, which optionally is substituted with fluorine, chlorine, bromine and/or iodine atoms and/or hydroxy, oxo, carboxy, aminocarbonyl, alkoxy carbonyl, amino, aldehyde or alkoxy groups with up to 30 carbon atoms and/or optionally is interrupted and/or substituted by one or more heteroatoms from the series N, P, As, O, S, Se and whereby radicals  $R^{11}$  and  $R^{12}$ ,  $R^{13}$  and  $R^{14}$ ,  $R^{15}$  and  $R^{16}$ , as well as  $R^{17}$  and  $R^{18}$  together optionally can stand for an oxygen atom, and n, m and p, independently of one another, mean 1 or 2, and whose central atom is a radionuclide of the elements of atomic numbers

27, 29-32, 37-39, 42-51, 62, 64, 70, 75, 77, 82 or 83, for the production of agents that are administered topically in the treatment of proliferative diseases.

20. Use of complexes whose ligand is an  $N_2S_2$  derivative of general formula III



whereby  $R^{21}$  to  $R^{32}$  are the same or different and in each case stand for a hydrogen atom and/or for an unbranched, branched, cyclic or polycyclic  $C_1$ - $C_{100}$  alkyl,  $C_1$ - $C_{100}$  alkenyl,  $C_1$ - $C_{100}$  alkynyl,  $C_1$ - $C_{100}$  aryl,  $C_1$ - $C_{100}$  alkylaryl and/or  $C_1$ - $C_{100}$  arylalkyl radical, which optionally is substituted with fluorine, chlorine, bromine and/or iodine atoms and/or hydroxy, oxo, carboxy, aminocarbonyl, alkoxycarbonyl, amino, aldehyde or alkoxy groups with up to 30 carbon atoms and/or optionally is interrupted and/or substituted by one or more heteroatoms from the series N, P, As, O, S, Se, and whose central atom is a radionuclide of the elements of atomic numbers 27, 29-32, 37-39, 42-51, 62, 64, 70, 75, 77, 82 or 83, for the production of agents that are administered topically in the treatment of proliferative diseases.

21. Use of compounds according to one of claims 18 to 20, wherein the radionuclide is selected from the group  $^{99m}\text{Tc}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{67}\text{Cu}$ ,  $^{90}\text{Y}$  and  $^{107}\text{Ag}$ .

22. Use of colloidal solutions for the production of agents for the treatment of proliferative diseases, wherein the colloidal solution is labeled with a radionuclide of elements Ag, As, At, Au, Ba, Bi, Br, C, Co, Cr, Cu, F, Fe, Ga, Gd, Hg, Ho, I, In, Ir, Lu, Mn, N, O, P, Pb, Pd, Pm, Re, Rh, Ru, Sb, Sc, Se, Sm, Sn, Tb, Tc or Y.

23. Use of colloidal solutions according to claim 22, wherein the colloidal solution is labeled with a radionuclide that is selected from the group  $^{99m}\text{Tc}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{67}\text{Cu}$ ,  $^{90}\text{Y}$ ,  $^{153}\text{Sm}$ ,  $^{160}\text{Tb}$ ,  $^{162}\text{Tb}$ ,  $^{198}\text{Au}$  and  $^{107}\text{Ag}$ .

24. Use of colloidal solutions according to claim 22, wherein the colloid is produced by a redox reaction in the presence of a radioactive salt.

25. Use of colloidal solutions according to claim 22, wherein the colloid is produced by changing the pH in an aqueous or alcoholic solution in the presence of a radioactive salt.

26. Use of colloidal solutions according to claim 22, wherein the particle size of the colloidal particles is between 5 and 1000 nm.

27. Use of colloidal solutions according to claim 22, wherein the particle size of the colloidal particles is between 300 and 600 nm.

28. Use of colloidal solutions according to claim 22, wherein the colloidal solution is stabilized with the aid of surfactants or other amphiphilic substances.

29. Use of radiolabeled sulfur colloids for the production of agents for the treatment of proliferative diseases.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
22



[Key to Figure 3:]

lokale Applikationssysteme = topical administration systems

Diffusion = diffusion

Doppelballon = double balloon

Mehrkammerballon = multichamber balloon

Hydrogelballon = hydrogel balloon

beschichteter Stent = coated stent

druckgetrieben = pressure-driven

poröser Ballon = porous balloon

mikroporöser Ballon = microporous balloon

makroporöser Ballon = macroporous balloon

Ballon im Ballon = balloon in a balloon

kanulierter Ballon = cannulated balloon

Infusionsschlauch = infusion hose

mechanisch = mechanical

Iontophoretischer Ballon = iontophoretic balloon


Nadelkatether = needle catheter

WO 99/13920

PCT/EP98/05741

1/3

Fig. 1



[Key:]

Katheter = catheter

WO 99/13920

PCT/EP98/05741

2/3

Fig. 2



W.N.1839 Katheter




W.N.1839 dyn., 1h



[Key:]

Katheter = catheter

Fig. 3



54505AUSA

<b>COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY</b> (Includes Reference to PCT International Applications)	ATTORNEY'S DOCKET NUMBER <b>SCH 1737</b>
--	---

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought of the invention entitled

**PROCESS FOR THERAPEUTIC TREATMENT OF PROLIFERATIVE DISEASES**

the specification of which (check only one item below):

- ☐ is attached hereto.
- ☐ was filed as United States application

Serial No. \_\_\_\_\_

on \_\_\_\_\_

and was amended

on \_\_\_\_\_ (if applicable).

- ☒ was filed as PCT international application

Number PCT/EP98/05741 on 10 September 1998

and was amended under PCT Article 19

on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim priority benefits under Title 35, United States Code, §119 of the following United States Provisional Application and of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed

PRIOR U.S. PROVISIONAL AND FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:			
COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
Germany	197 41 694.2	18 September 1997	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
Germany	197 41 695.0	18 September 1997	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
Germany	197 42 880.0	23 September 1997	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

# Combined Declaration For Patent Application and Power of Attorney (Continued)

ATTORNEY'S DOCKET NUMBER  
SCH 1737

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
PCT APPLICATION NO	PCT FILING DATE	U.S. SERIAL NUMBER ASSIGNED (if any)		

POWER OF ATTORNEY: As a named inventor, I hereby appoint William Mullen (19,544), John L. White (17,746), Anthony J. Zelano (17,369), Alan E. J. Brangan (20,565), John R. Jones (24,983), Gary B. Shubin (32,404), Bron P. Heaney (32,532), Richard J. Traverso (30,392), John A. Supp (33,103), Richard M. Lebowitz (37,067), John H. Thomas (33,460), Catherine M. Joyce (40,568), James T. Moore (35,619), James E. Rutland (37,432), Nancy Ann Rod (44,013) and Jennifer J. Brangan (40,921) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Send Correspondence to: MULLEN, WHITE, ZELANO & BRANGAN, P.C.  
Arlington Courthouse Plaza I, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201

Telephone No  
703/243-6333

Direct Telephone Calls to

FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
1	DINKELBORG	Ludger	
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
1	Berlin	Germany DEX	Germany
POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
	Ottowinstrasse 7	Berlin	D-13465 Germany
FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
2	HILGER	Christoph-Stephan	
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
2	Berlin	Germany DEX	Germany
POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
	Langemannstr. Weg 24	Berlin	13503 Berlin
FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
3	HELDMANN	Dieter	
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
3	Berlin	Germany DEX	Germany
POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
	Conradstraße 38	Berlin	D-13509 Berlin
FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
4	SLUME	Friedhelm	
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
4	Berlin	Germany DEX	Germany
POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
	Nussliherstrasse 47	Berlin	D-13505 Germany

**Combined Declaration for Patent Application and Power of Attorney (Continued)**

(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NUMBER

SCH 1737

205	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
206	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
207	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
208	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
209	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
210	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
211	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
212	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
213	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
214	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
215	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
216	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
217	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
218	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
219	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201	DATE	SIGNATURE OF INVENTOR 207	DATE
<i>[Signature]</i>	23.03.00		
SIGNATURE OF INVENTOR 202	DATE	SIGNATURE OF INVENTOR 208	DATE
<i>[Signature]</i>	24.03.00		
SIGNATURE OF INVENTOR 203	DATE	SIGNATURE OF INVENTOR 209	DATE
<i>[Signature]</i>	24.03.00		
SIGNATURE OF INVENTOR 204	DATE	SIGNATURE OF INVENTOR 210	DATE
<i>[Signature]</i>	24.03.00		
SIGNATURE OF INVENTOR 205	DATE	SIGNATURE OF INVENTOR 211	DATE
SIGNATURE OF INVENTOR 206	DATE	SIGNATURE OF INVENTOR 212	DATE